Sponsors (10)
The bill speeds and hardens federal controls over a class of potent synthetic opioids—potentially reducing illicit supply and aiding enforcement—but does so in ways that could criminalize trace possession, constrain research and treatment options, and weaken procedural safeguards in rulemaking.
People at risk of overdose and the general public may see reduced availability of dangerous nitazene-related opioids, potentially lowering overdose incidents.
Law enforcement agencies can permanently control and criminalize a broad class of potent nitazene-related synthetic opioids, making prosecution and interdiction of these substances simpler.
Federal agencies (DEA/Attorney General) can publish a Federal Register list identifying controlled compounds, giving clinicians, labs, and suppliers clearer notice about what is regulated and how to comply.
People (including casual possessors or those with trace amounts in mixtures) risk criminal penalties because the definition covers 'any quantity' and includes salts/isomers unless explicitly exempted.
Patients with opioid use disorder or those who might benefit from investigational controlled-research therapies could lose access to treatments or clinical trials if related compounds become unavailable for medical research.
Researchers and clinicians will face tighter restrictions and additional paperwork to study or handle these compounds, likely slowing scientific and medical research into potential treatments and harms.
Based on analysis of 6 sections of legislative text.
Creates a broad Schedule I listing for nitazene-class synthetic opioids, makes prior temporary emergency listings permanent, and requires AG implementation rules within one year.
Official title: To amend the Controlled Substances Act to permanently schedule 2-benzylbenzimidazole opioids (commonly referred to as nitazenes) as Schedule 1 controlled substances, and for other purposes.
Introduced March 18, 2026 by Robert E. Latta · Last progress March 18, 2026
The bill adds a new, broadly defined class of synthetic opioids called "2-benzylbenzimidazole opioids" (commonly referred to as nitazenes and related substances) to Schedule I of the Controlled Substances Act, making those chemicals, their salts, isomers, and specified named analogues illegal at the federal level unless specifically exempted. It also converts any substances already temporarily scheduled under emergency authority into permanent Schedule I status on enactment and requires the Attorney General to publish implementing rules (including as interim final rules) within one year, with an opportunity for public comment and a later final rule under the Administrative Procedure Act.